Oncology Business Management | Specialty

Puma Begins Phase III Development of Neratinib in Breast Cancer

September 6th 2013

Puma Biotechnology is a Los Angeles-based development stage biopharmaceutical company that has spent the last couple of years focused on the development of its lead drug candidate, neratinib (PB272).

The Affordable Care Act: What Nurses Need to Know

September 5th 2013

A hot topic of discussion at the American Society of Clinical Oncology (ASCO) meeting in June was the Patient Protection and Affordable Care Act (often referred to as the ACA) and what it means for the future of oncology care in the United States.

Novel Drug Studies Yield Biomarker Candidates for Prostate Cancer Bone Turnover

September 4th 2013

Prostate cancer has a propensity to metastasize to bone. High turnover ultimately results in a net loss of bone tissue; prostate cancer treatment contributes to the loss of bone integrity, as androgen- deprivation therapy often causes abnormally low bone density

Sorafenib Receives Priority Review for Rare Thyroid Cancer

August 27th 2013

The FDA has given priority review designation to sorafenib for the treatment of locally advanced or metastatic RAI-refractory differentiated thyroid cancer.

Taking Care of Business: Regional Urology Offers Consistent Care Despite Tumultuous Times

August 22nd 2013

Change may not always be pleasant, but it is inevitable, and nowhere has that been more evident recently than in US healthcare; however, for the physicians at Regional Urology in Shreveport, Louisiana, these changes are really just business as usual.

Dr. Van Tine on Identifying Biomarkers in Sarcomas

August 12th 2013

Brian A. Van Tine, MD, PhD, Assistant Professor, Washington University School of Medicine in St. Louis, discusses identifying biomarkers in sarcomas.

Dr. Saenger on the Need for Immunotherapy Biomarkers

August 7th 2013

Yvonne M. Saenger, MD, Assistant Professor in Medicine and Dermatology, Hematology and Medical Oncology, Mount Sinai School of Medicine, discusses the need for biomarkers for immunotherapies.

Mining the Pipeline: Leading Investigational Products and Areas of Unmet Need

August 7th 2013

The oncology pipeline is crowded, despite the fact that the agents in development target a broad range of tumor types.

Ben Jones on Sequestration and Reimbursement

August 5th 2013

Ben Jones, Senior Director of Government Relations & Public Policy at McKesson Specialty Health & The US Oncology Network, discusses the impact of sequestration on drug and physician reimbursement.

Performance Metrics in Oncology

July 24th 2013

In 2011, the Medicare Electronic Health Record Incentive Program began paying physicians and hospitals for the measurement and reporting of performance metrics through the utilization of certified electronic medical record software.

Dr. Weber on Optimal Therapy Sequences in Melanoma

July 23rd 2013

Jeffrey S. Weber, MD, PhD, from the Moffitt Cancer Center and Research Institute, discusses sequencing immunologic and targeted therapies in patients with advanced BRAF-mutated melanoma.

FDA Approves Afatinib for Metastatic NSCLC

July 12th 2013

The FDA has approved afatinib, along with a companion diagnostic, to treat patients with metastatic non-small cell lung cancer who express specific types of EGFR mutations.

Dr. Gogineni Comments on Oncology Drug Shortages

July 11th 2013

Keerthi Gogineni, MD, MSHP, medical oncologist, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, comments on oncology drug shortages in the U.S.

Cost Versus Quality in Different Sites of Cancer Care

July 8th 2013

More oncology providers have shifted toward consolidation of practices to remain viable. In the last 4 years, 524 private practices have entered into agreements with or have been acquired by hospitals.

Priority Review Granted to Neoadjuvant Breast Cancer Regimen

July 2nd 2013

The FDA has granted priority review to a regimen of pertuzumab, trastuzumab, and docetaxel for the treatment of patients with HER2-positive early-stage breast cancer.

Conclusion: Key Take-Away Points and Cardiac Safety

July 1st 2013

Unmet Needs in Renal Cell Carcinoma

July 1st 2013

Immune Checkpoint Inhibition in Renal Cell Carcinoma

July 1st 2013

Novel Agents in Development for Renal Cell Carcinoma

July 1st 2013

INTORSECT Trial: Second-Line Temsirolimus Versus Sorafenib

July 1st 2013